FNIH-defined Sarcopenia Predicts Adverse Outcomes Among Community-Dwelling Older People in Taiwan: Results From I-Lan Longitudinal Aging Study
Overview
Authors
Affiliations
Background: To evaluate the predictive validity of sarcopenia defined by the Foundation for the National Institutes of Health (FNIH) Sarcopenia Project among Asian older adults.
Methods: Data of the I-Lan Longitudinal Aging Study were obtained for analysis. Overall, 1,839 community-dwelling people aged 50 years and older, capable of completing a 6-m walk, with life expectancy of more than 6 months, and not institutionalized at time of data collection were enrolled for study. Data for subjects aged 65 years and older were obtained for study. The outcome measures were all-cause mortality and a composite adverse outcome which includes hospitalizations, emergency department visits, institutionalization, and falls.
Results: Data of 728 eligible elderly participants (73.4 ± 5.4 years; 52.9% males) were analyzed. The prevalence of FNIH-diagnosed sarcopenia was 9.5%: 11.9% males; 6.7% females. Participants having FNIH-defined sarcopenia were considerably older, frailer, more obese, with poorer physical performance than nonsarcopenic subjects (All p < .001); during mean follow-up of 32.9 ± 8.8 months, they also had 3.8 times higher risk of dying, independent of age, sex, multimorbidity, cognitive function, and nutritional status (hazard ratio = 3.8; 95% confidence interval = 1.26-11.45; p = .018). Moreover, sarcopenia defined by grip strength-BMI ratio (WeakBMI) showed stronger association with composite adverse outcomes than traditional handgrip strength (hazard ratio = 1.99; 95% confidence interval = 1.01-3.93; p = .047 vs hazard ratio = 1.80; 95% confidence interval = 0.89-3.62; p = .102 in fully-adjusted model).
Conclusion: Among community-dwelling older people in Taiwan, participants with FNIH-defined sarcopenia had a significantly greater risk of all-cause mortality and composite falls, emergency department visits, institutionalization, and hospitalization.
Delbari A, Azimi A, Pakmehr A, Saatchi M, Bidkhori M, Tabatabaei F Med J Islam Repub Iran. 2025; 38():114.
PMID: 39781315 PMC: 11707710. DOI: 10.47176/mjiri.38.114.
Yamagiwa D, Makino K, Katayama O, Yamaguchi R, Georg V, Yamashiro Y J Cachexia Sarcopenia Muscle. 2024; 16(1):e13634.
PMID: 39575623 PMC: 11670167. DOI: 10.1002/jcsm.13634.
Cataltepe E, Ceker E, Fadiloglu A, Varan H BMC Geriatr. 2024; 24(1):875.
PMID: 39448925 PMC: 11515595. DOI: 10.1186/s12877-024-05418-y.
Liu S, He Y, Yu G, Song C, Wang D, Liu L Ann Med. 2024; 56(1):2390169.
PMID: 39129458 PMC: 11321103. DOI: 10.1080/07853890.2024.2390169.
Kwon R, Cho Y, Park E, Lee S, Choi J, Lee Y Medicine (Baltimore). 2024; 102(52):e36644.
PMID: 38206714 PMC: 10754618. DOI: 10.1097/MD.0000000000036644.